Sustained response of refractory prolymphocytic leukemia to fludarabine.
A patient with de novo prolymphocytic leukemia who was refractory to chemotherapy and splenic radiation achieved a dramatic sustained response following 3 courses of therapy with fludarabine.
Sporn
J R
JR
Division of Hematology-Oncology, University of Connecticut Health Center, Farmington.
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D015463:Leukemia, Prolymphocytic / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D007958:Leukocyte Count; D008297:Male; D012074:Remission Induction; D013154:Spleen / Q000473:pathology; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D014740:Vidarabine; C024352:fludarabine